20-Mar-2026
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
PRNewswire (Thu, 12-Mar 8:30 AM ET)
PRNewswire (Fri, 6-Mar 8:00 AM ET)
Halozyme to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 25-Feb 8:30 AM ET)
PRNewswire (Tue, 17-Feb 4:01 PM ET)
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
PRNewswire (Tue, 10-Feb 4:05 PM ET)
Halozyme Lifts Multi-Year Guidance on Royalty Surge and Strategic Acquisitions
Market Chameleon (Wed, 28-Jan 2:45 AM ET)
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
PRNewswire (Wed, 28-Jan 6:30 AM ET)
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
PRNewswire (Tue, 20-Jan 4:05 PM ET)
PRNewswire (Thu, 8-Jan 8:00 AM ET)
Globe Newswire (Mon, 5-Jan 7:00 AM ET)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Halozyme Therapeutics trades on the NASDAQ stock market under the symbol HALO.
As of March 20, 2026, HALO stock price climbed to $63.43 with 2,730,658 million shares trading.
HALO has a beta of -0.02, meaning it tends to be less sensitive to market movements. HALO has a correlation of 0.00 to the broad based SPY ETF.
HALO has a market cap of $7.49 billion. This is considered a Mid Cap stock.
Last quarter Halozyme Therapeutics reported $452 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$2.39.
In the last 3 years, HALO traded as high as $82.22 and as low as $29.85.
The top ETF exchange traded funds that HALO belongs to (by Net Assets): VTI, IJH, VB, VBK, XBI.
HALO has underperformed the market in the last year with a price return of -1.4% while the SPY ETF gained +16.6%. HALO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.8% and -5.8%, respectively, while the SPY returned -4.4% and -3.3%, respectively.
HALO support price is $62.08 and resistance is $64.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HALO shares will trade within this expected range on the day.
